Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GPC (FSE:GPC; GPCB) fell EUR 4.74 (60%) to EUR 3.22 on Wednesday after additional data from the Phase III SPARC
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury